Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Roman Freixa Pamias"'
Autor:
Francisco Marin, Marcelo Sanmartin Fernandez, Gonzalo Baron-Esquivias, Vivencio Barrios, Inaki Lekuona, Alejandro I Perez-Cabeza, Jaime Masjuan, Esther Recalde del Vigo, Jose Manuel Vazquez Rodriguez, Roman Freixa-Pamias, Vanessa Roldan Schilling, Fernando Arribas, Carles Rafols Priu, Manuel Anguita Sanchez
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 3 (2023)
Aim: It is not well known how comorbidities may change the prognosis of atrial fibrillation (AF) patients. This study was aimed to analyze the impact of cardiovascular disease on this population. Materials & methods: EMIR was a multicenter, prospec
Externí odkaz:
https://doaj.org/article/eda29beddbb14fddb75450f8299c618d
Publikováno v:
Revista Española de Cardiología (English Edition). 76:287-293
Autor:
Marcelo Sanmartín Fernández, Manuel Anguita Sánchez, Fernando Arribas, Gonzalo Barón-Esquivias, Vivencio Barrios, Juan Cosin-Sales, María Asunción Esteve-Pastor, Roman Freixa-Pamias, Iñaki Lekuona, Alejandro I. Pérez-Cabeza, Isabel Ureña, José Manuel Vázquez Rodríguez, Carles Rafols Priu, Francisco Marin
Publikováno v:
Cardiology Journal. 29:601-609
The aim of the study was to evaluate the performance of the 2MACE in patients with atrial fibrillation (AF) treated with rivaroxaban and to improve the accuracy of 2MACE.This was a post-authorization and observational study of AF adults treated with
Autor:
Alberto Cordero, Mª. Rosa Fernández Olmo, Gustavo A. Cortez Quiroga, Cesar Romero‐Menor, Lorenzo Fácila, José Seijas‐Amigo, Juan Rondán Murillo, Miriam Sandin, Moisés Rodríguez‐Mañero, María C. Bello Mora, Alfonso Valle, Aisa Fornovi, Roman Freixa Pamias, Jordi Bañeras, Pedro Blanch García, María Milagros Clemente Lorenzo, Sergio Sánchez‐Álvarez, Luis López‐Rodríguez, José R. González‐Juanatey
Publikováno v:
European Journal of Clinical Investigation. 52
Monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 55%, regardless of baseline treatments. Nonetheless, the effect of other lipid parameters, such as chole
Autor:
Pedro Armario, Roman Freixa-Pamias
Publikováno v:
Clínica e Investigación en Arteriosclerosis. 33:254-256
Autor:
José Seijas-Amigo, Alberto Cordero, Rosa F. Olmo, Gustavo A. Cortez Quiroga, Lorenzo Fácila, Ángel Salgado-Barreira, Francisco Reyes-Santías, Cesar Romero-Menor, Juan Rondán Murillo, Moisés Rodríguez-Mañero, María C. Bello Mora, Alfonso Valle, Miriam Sandin, Roman Freixa Pamias, Jordi Bañeras, Pedro Blanch García, Milagros Clemente Lorenzo, Sergio Sánchez-Alvarez, Luis López-Rodríguez, José R. González-Juanatey
Publikováno v:
Journal of cardiovascular pharmacology. 81(1)
Low-density lipoprotein cholesterol (LDLc) is the lead effector of atherosclerosis and main treatment target. Bempedoic acid is a novel oral drug in the therapeutic armamentarium which is able to reduce LDLc. The objectives of this study were (1) to
Autor:
Ahmet Celik, Maria Christiane Valeria Braga Braile-Sternieri, Denis Andreev, Yury Grinshtein, Andrzej Lubiński, Hans Prozesky, Olga Mirolyubova, Yaroslav Malynovsky, Michel GALINIER, Andrzej Madej, Felix Perez-Villa, Dariusz Kosior, Mandeep Mehra, Elena Shutemova, John Cleland, PASCUAL BORDES SISCAR, Henk Verheul, ROMAN FREIXA-PAMIAS
Publikováno v:
New England Journal of Medicine, 379(14), 1332-1342. MASSACHUSETTS MEDICAL SOC
Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and improve outcomes for patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa09983d0a8f132bd68948e856db311e
http://hdl.handle.net/11379/518287
http://hdl.handle.net/11379/518287
Autor:
Aleksandr Svistov, Oksana Drapkina, William Strain, YAN CARLOS DUARTE VERA, Lars Kober, Manuel Gómez-Bueno, Konstantin Ramshev, Miguel Urina, Kamal Sharma, Zbigniew Pijanowski, Peter Olexa, Celina Wojciechowska, Albert HAGEGE, Jan Krupicka, Marcelo Sanmartin-Fernandez, Michel GALINIER, Vladimir Rafalskiy, John Mcmurray, Roman Libis, Angus Nightingale, Fernando Lanas, MICHELE SENNI, Richard Bogle, Marta Negrusz-Kawecka, Jose Silva-Cardoso, Michael Zile, José Albuquerque De Figueiredo Neto, Biykem Bozkurt, Philippe Gosse, Elena Shutemova, Fernando Manzur, Raj Mohindra, Gian Battista Danzi, DİLEK URAL, ROMAN FREIXA-PAMIAS
Publikováno v:
European Journal of Heart Failure, 15, 1062-73
European Journal of Heart Failure
European Journal of Heart Failure, 15, 9, pp. 1062-73
European Journal of Heart Failure
European Journal of Heart Failure, 15, 9, pp. 1062-73
Item does not contain fulltext AIMS: Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the renin-angiotensin-aldosterone system (RAAS), potentially beneficial counte
Autor:
Aleksandr Svistov, Oksana Drapkina, William Strain, YAN CARLOS DUARTE VERA, Lars Kober, Julio Núñez, Konstantin Ramshev, Manuel Martinez-Selles, Miguel Urina, Thomas Muenzel, Kamal Sharma, Sotir Marchev, MEHMET BIRHAN YILMAZ, Zbigniew Pijanowski, Peter Olexa, Albert HAGEGE, Pardeep Jhund, Mamas Mamas, Jan Krupicka, Marcelo Sanmartin-Fernandez, Michel GALINIER, Vladimir Rafalskiy, John Mcmurray, Roman Libis, Angus Nightingale, Fernando Lanas, MICHELE SENNI, Richard Bogle, Michael Zile, José Albuquerque De Figueiredo Neto, Biykem Bozkurt, Philippe Gosse, Evgeny Zhilyaev, Elena Shutemova, Fernando Manzur, Raj Mohindra, Natalie Bello, Gian Battista Danzi, DİLEK URAL, ROMAN FREIXA-PAMIAS
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
The New England journal of medicine, 371(11), 993-1004. United States (2014).
McMurray, J J V, Packer, M, Desai, A S, Gong, J, Lefkowitz, M P, Rizkala, A R, Rouleau, J L, Shi, V C, Solomon, S D, Swedberg, K, Zile, M R & PARADIGM-HF Investigators and Committees 2014, ' Angiotensin-neprilysin inhibition versus enalapril in heart failure ', The New England Journal of Medicine, vol. 371, no. 11, pp. 993-1004 . https://doi.org/10.1056/NEJMoa1409077
Universidad de Barcelona
The New England journal of medicine, 371(11), 993-1004. United States (2014).
McMurray, J J V, Packer, M, Desai, A S, Gong, J, Lefkowitz, M P, Rizkala, A R, Rouleau, J L, Shi, V C, Solomon, S D, Swedberg, K, Zile, M R & PARADIGM-HF Investigators and Committees 2014, ' Angiotensin-neprilysin inhibition versus enalapril in heart failure ', The New England Journal of Medicine, vol. 371, no. 11, pp. 993-1004 . https://doi.org/10.1056/NEJMoa1409077
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients.METHODS: In this double-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057eafc951e64542d7bae65b6ab4fe32
http://hdl.handle.net/2445/178508
http://hdl.handle.net/2445/178508
Autor:
Codinach Huix P, ROMAN FREIXA-PAMIAS
Publikováno v:
Europe PubMed Central
The diabetic cardiomyopathy is a disease caused by diabetes and is characterised by the presence of diastolic and/or systolic left ventricular dysfunction. Diabetes may produce metabolic alterations, interstitial fibrosis, myocellular hypertrophy, mi